The commencement of inavolisib, a small molecule designed to selectively inhibit mutant PIK3CA, immediately resulted in grade 3 hyperglycemia that persisted despite the commencement of metformin and insulin glargine. This evidence concerns the gene PIK3CA and Hyperglycemia.